Spots Global Cancer Trial Database for boserolimab
Every month we try and update this database with for boserolimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) | NCT04165096 | Carcinoma, Non-... | Pembrolizumab Boserolimab MK-4830 diphenhydramine acetaminophen MK-0482 | 18 Years - | Merck Sharp & Dohme LLC | |
| Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | NCT04924101 | Small Cell Lung... | Pembrolizumab MK-4830 Boserolimab Lenvatinib Etoposide Cisplatin Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) | NCT04165096 | Carcinoma, Non-... | Pembrolizumab Boserolimab MK-4830 diphenhydramine acetaminophen MK-0482 | 18 Years - | Merck Sharp & Dohme LLC | |
| Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | NCT04924101 | Small Cell Lung... | Pembrolizumab MK-4830 Boserolimab Lenvatinib Etoposide Cisplatin Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | NCT04924101 | Small Cell Lung... | Pembrolizumab MK-4830 Boserolimab Lenvatinib Etoposide Cisplatin Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | NCT04165070 | Carcinoma, Non-... | Pembrolizumab Carboplatin Paclitaxel Pemetrexed Vibostolimab Boserolimab MK-4830 MK-0482 | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | NCT03396445 | Pharmacokinetic... Solid Tumor Carcinoma, Non-... Triple Negative... | Boserolimab Pembrolizumab Pemetrexed Carboplatin Nab-paclitaxel | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
